FIGURE 5.

A, C, Notable AEs were graded 0‐2 CRS in first‐time anti‐CD19‐CAR T‐cell therapy, and 2‐4 CRS in the second‐time anti‐CD19‐CAR T‐cell therapy. B, D, Hematological toxicity was grades 1‐3 in first‐time anti‐CD19‐CAR T‐cell therapy and grades 3 and 4 in the second‐time anti‐CD19‐CAR T‐cell therapy. E‐H, Serum levels of IL‐6, IL‐2R, TNF‐α, and IL‐8 were observed in the 2 times of anti‐CD19‐CAR T‐cell therapy. I, ALC was reduced significantly after pretreatment of fludarabine combined with cyclophosphamide lymphodepletion regimen, and the ALC levels could not be changed by the ibrutinib therapy